BridgeMD
Individualized anti-platelet therapy in patients with stable coronary artery disease undergoing stenting
EU CTIS ID: 2023-504078-39-01
What this study is testing
The aim of this study is to assess if a CYP2C19 genotype guided P2Y12-inhibitor monotherapy improves P2Y12-receptor mediated platelet inhibition by measuring platelet reactivity units using the VerifyNow. The primary end point of our study will be levels of platelet reactivity, measured as PRU using the VerifyNow system, of CYP2C19 genotype guided P2Y12-inhibitor monotherapy versus standard DAPT at 30 days after randomization.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients of 18 years or older
- Patients with Chronic Coronary Syndrome (CCS) undergoing successful elective percutaneous coronary intervention (PCI)
- Patients with written informed consent as approved by the ethics committee
You likely can't join if
- • Contraindication to aspirin
- • Suboptimal result of stenting as defined by the operator, preferably explained according the complex-PCI criteria
- • Treatment with a strong CYP3A4 inhibitor or inducer
- • Treatment with a strong CYP2C19 inhibitor or inducer
- • Contraindication to ticagrelor, prasugrel or clopidogrel
- • Planned cardiac valve surgery
See the full eligibility criteria
- Patients of 18 years or older
- Patients with Chronic Coronary Syndrome (CCS) undergoing successful elective percutaneous coronary intervention (PCI)
- Patients with written informed consent as approved by the ethics committee
- • Contraindication to aspirin
- • Suboptimal result of stenting as defined by the operator, preferably explained according the complex-PCI criteria
- • Treatment with a strong CYP3A4 inhibitor or inducer
- • Treatment with a strong CYP2C19 inhibitor or inducer
- • Contraindication to ticagrelor, prasugrel or clopidogrel
- • Planned cardiac valve surgery
- • Need for chronic oral anticoagulation
- • PCI when admitted for ACS
- • Life expectancy < 1 year
- • Unable or unwilling to provide informed consent
- • Pregnancy
- • History of definite stent thrombosis
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.